Table 1.

Cannabinoid drugs as potential agents to treat prepulse inhibition of startle (PPI) deficits in schizophrenia.

Cannabinoid drug	Effect on SHR's PPI	Limitations/advantages
WIN 55212,2	Attenuates the deficit	Induces psychotomimetic effects in animal models.
Rimonabant	Worsens the deficit	Is associated with increased symptoms of depression and anxiety.
AM 404	Does not modify PPI
Cannabidiol	Attenuates the deficit	Displays antipsychotic properties in humans and in other behavioral abnormalities in animal models. Is safe in animals and humans.